'Daedalus' Platform Introduces Major Advances in Recombinant Protein Production from Human Cell Lines by Scherer, Erin
November 14, 2011 SCIENCE SPOTLIGHT 
 
1 Volume 1, Issue 2 | Fred Hutchinson Cancer Research Center 
 
'Daedalus' Platform Introduces Major Advances 
in Recombinant Protein Production from Human 
Cell Lines 
November 14, 2011 
      EM Scherer 
To ensure proper protein folding and post-translational modifications that are important for biological 
activity, recombinant human proteins should be expressed in human cell lines. However, this 
approach frequently suffers from low yields, costly transfection reagents and/or time-consuming 
techniques (e.g., the selection of optimal expression clones). These concerns are particularly 
relevant when high protein yields are required, as is the case for protein structure determination or 
for therapeutic applications. Graduate students Ashok Bandaranayake and Colin Correnti, their 
advisor and member of the Basic Sciences Division, Dr. Roland Strong, and colleagues developed a 
protein expression system that overcomes many of the above limitations. Appropriately named after 
a skilled craftsman in Greek mythology, Daedalus, this platform features an innovative lentiviral 
vector containing a minimized, ubiquitous chromatin opening element (UCOE0.7). This vector vastly 
enhances and sustains stable protein expression in commercially available human cell lines whose 
secretory pathways and adaptation to serum-free media facilitate purification.  
Using Daedalus, the authors proceeded from lentiviral transduction to protein structure determination 
in a mere 18 days for one of the target proteins. In total, Bandaranayake et al. improved the 
production of highly pure, properly folded protein for 12 out of 14 targets, with yields ranging from 
10-100 mg/L. They also showed that the recombinant human cytokines produced by Daedalus 
exhibited identical immune activity in cellular assays as commercial reagents, indicating that this 
platform may be appropriate for the manufacture of protein therapeutics. Although lentiviral vectors 
are generally constrained in terms of the amount of exogenous DNA they can package, the authors 
suggest that the current 70kDa limit on protein size may be readily overcome. Indeed, the minor 
vector modifications they propose will likely soon render Daedalus capable of producing full-length 
antibodies. 
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